

# Alice Laroni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/286949/publications.pdf>

Version: 2024-02-01

75  
papers

3,745  
citations

159585

30  
h-index

133252

59  
g-index

77  
all docs

77  
docs citations

77  
times ranked

5963  
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e426-e438.	5.8	23
2	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.	1.9	53
3	A real-world study of alemtuzumab in a cohort of Italian patients. <i>European Journal of Neurology</i> , 2022, 29, 257-266.	3.3	15
4	Caregiver Involvement in MS: Duty or Disruption?. <i>Neurology and Therapy</i> , 2022, 11, 9-20.	3.2	3
5	High or increasing serum NfL is predictive of impending multiple sclerosis relapses. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103535.	2.0	18
6	Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study. <i>CNS Drugs</i> , 2022, 36, 83-96.	5.9	4
7	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. <i>EBioMedicine</i> , 2022, 80, 104042.	6.1	54
8	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2106-2111.	3.0	30
9	COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2126-2136.	3.0	34
10	Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 15-27.	1.8	18
11	Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups. <i>Frontiers in Immunology</i> , 2021, 12, 633167.	4.8	11
12	Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy. <i>Italian Journal of Pediatrics</i> , 2021, 47, 69.	2.6	3
13	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117385.	0.6	9
14	Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021, 18, 2579-2588.	4.4	17
15	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , 2021, 72, 103581.	6.1	184
16	Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118089.	0.6	1
17	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. <i>Lancet Neurology</i> , The, 2021, 20, 917-929.	10.2	42
18	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , 2020, 17, 200-207.	4.4	39

#	ARTICLE	IF	CITATIONS
19	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	2.0	2
20	Tailoring B cell depletion therapy in MS according to memory B cell monitoring. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	30
21	Magnetic Resonance Imaging Finding of Periodontal and Inferior Alveolar Nerve Inflammation in a Subject With Trigeminal Neuralgia. <i>Headache</i> , 2020, 60, 2631-2632.	3.9	1
22	Assessing upper limb function in multiple sclerosis using an engineered glove. <i>European Journal of Neurology</i> , 2020, 27, 2561-2567.	3.3	4
23	Cladribine vs other drugs in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	32
24	Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. <i>European Journal of Neurology</i> , 2020, 27, 2047-2055.	3.3	18
25	CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1450.	2.4	26
26	Impact of treatment on cellular immunophenotype in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	17
27	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102059.	2.0	4
28	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.	1.9	0
29	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1263-1272.	3.0	36
30	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116423.	0.6	6
31	Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study. <i>Journal of Neurology</i> , 2019, 266, 2440-2446.	3.6	16
32	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , 2019, 20, 263.	1.6	58
33	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. <i>Neurological Sciences</i> , 2019, 40, 1383-1391.	1.9	11
34	Enhancing natural killer cells is beneficial in multiple sclerosis – Yes. <i>Multiple Sclerosis Journal</i> , 2019, 25, 510-512.	3.0	11
35	Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. <i>Journal of Neurology</i> , 2019, 266, 707-716.	3.6	14
36	Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 261-267.	1.9	22

#	ARTICLE	IF	CITATIONS
37	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.1	102
38	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839.	1.1	74
39	Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1133-1137.	3.0	32
40	A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	3.6	23
41	Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS. <i>Multiple Sclerosis Journal</i> , 2018, 24, 623-631.	3.0	8
42	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018, 265, 2851-2860.	3.6	43
43	Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 52-54.	2.0	9
44	Approved drugs for multiple sclerosis: the challenge of choice. <i>Lancet Neurology</i> , The, 2017, 16, 252-253.	10.2	8
45	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2017, 88, 2115-2122.	1.1	134
46	In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. <i>Immunology Letters</i> , 2017, 181, 109-115.	2.5	16
47	Teriflunomide treatment reduces B cells in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e403.	6.0	28
48	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , 2017, 140, 2814-2819.	7.6	51
49	Assessing association of comorbidities with treatment choice and persistence in MS. <i>Neurology</i> , 2017, 89, 2222-2229.	1.1	50
50	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	4
51	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , 2017, 38, 53-59.	1.9	25
52	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2016, 7, 606.	4.8	88
53	Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis. <i>Journal of Autoimmunity</i> , 2016, 72, 8-18.	6.5	95
54	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	3.0	249

#	ARTICLE	IF	CITATIONS
55	Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. <i>Immunology Letters</i> , 2015, 168, 183-190.	2.5	59
56	Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity. <i>Journal of Neuroimmunology</i> , 2014, 275, 54-55.	2.3	0
57	Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma?. <i>Journal of Neuroimmunology</i> , 2014, 275, 218.	2.3	0
58	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. <i>BMC Neurology</i> , 2014, 14, 103.	1.8	10
59	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014, 14, 65.	1.8	47
60	Mesenchymal stem cells as treatment for MS – progress to date. <i>Multiple Sclerosis Journal</i> , 2013, 19, 515-519.	3.0	62
61	Towards Clinical Application of Mesenchymal Stem Cells for Treatment of Neurological Diseases of the Central Nervous System. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1062-1076.	4.1	45
62	Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1236-1237.	3.0	30
63	Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 665-672.	4.1	29
64	T-cell trafficking in the central nervous system. <i>Immunological Reviews</i> , 2012, 248, 216-227.	6.0	157
65	A case of thyroiditis during natalizumab therapy for multiple sclerosis. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 408-409.	3.3	8
66	Neuroprotective features of mesenchymal stem cells. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 59-64.	1.7	195
67	IL-27 Imparts Immunoregulatory Function to Human NK Cell Subsets. <i>PLoS ONE</i> , 2011, 6, e26173.	2.5	47
68	Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. <i>Lancet Neurology</i> , The, 2011, 10, 649-656.	10.2	279
69	Three years of experience: the Italian registry and safety data update. <i>Neurological Sciences</i> , 2011, 31, 295-297.	1.9	28
70	Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. <i>Neurological Sciences</i> , 2011, 32, 181-182.	1.9	31
71	Can we kill an extra bird with the same stone?. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E124-E125.	1.9	1
72	Role of the innate immune system in the pathogenesis of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 221, 7-14.	2.3	268

#	ARTICLE	IF	CITATIONS
73	Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells. <i>Nature Immunology</i> , 2010, 11, 846-853.	14.5	407
74	Wernicke's syndrome during parenteral feeding: Not an unusual complication. <i>Nutrition</i> , 2009, 25, 142-146.	2.4	80
75	Multiple sclerosis and autoimmune diseases. <i>Journal of Neurology</i> , 2006, 253, 636-639.	3.6	41